Abbott Laboratories raised its 2026 profit guidance after Q2 delivered stronger-than-expected results, supported by improved performance across most business lines. The upward guide implies better forward earnings momentum, likely prompting a positive re-rating of expectations for 2026.
Abbott Laboratories raised its 2026 profit guidance after Q2 delivered stronger-than-expected results, supported by improved performance across most business lines. The upward guide implies better forward earnings momentum, likely prompting a positive re-rating of expectations for 2026.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
